Biopharmaceutical company Altimmune, Inc. (ALT) on Monday announced that the company will report results from a Phase 1 clinical trial of ALT-801 in overweight and obese subjects.
The company said it will discuss the results in a pre-market press release, conference call and webcast on September 28 at 8:30 a.m. ET.
Altimmune said it is focused on developing treatments for obesity and liver diseases.
ALT closed Monday's trading at $15.19, up $0.22 or 1.47%, on the NYSE. The stock further gained $0.60 or 3.95% in the after-hours trade.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.